UNSPSC 51422421: Fludrocortisone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C23H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V47IF0PVH4, chemically known as 9-fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate but more generally known as fludrocortisone acetate, which bears US NIH Compound Identifier 10572. European Medicines Agency schedules Fludrocortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02209MIG.

UNSPSC 51422421 Fludrocortisone acetate is a Commodity code for a synthetic corticosteroid pharmaceutical product, though recent state and local procurement activity under this code shows a significant mismatch: the only recent opportunity tagged to this code is a Seminole County, Florida IFB for naloxone and drug deactivation systems, which falls outside the scope of fludrocortisone acetate procurement. State and local governments use fludrocortisone acetate for treatment of adrenocortical insufficiency and related endocrine disorders, typically procured through health department pharmaceutical supply contracts, hospital systems, and public health agencies. The code nominal scope covers individual pharmaceutical commodities, which suggests buying occurs through health and human services departments, county health agencies, public hospitals, and specialized clinics. However, the recent opportunity record does not support ongoing active solicitation of fludrocortisone acetate itself at the state and local level.

The single recent opportunity posted under this code—Seminole County's IFB 60459723LAS, released June 30, 2026, with response due July 26, 2023—addresses naloxone and drug deactivation systems for community health initiatives rather than fludrocortisone acetate. This suggests either a coding error in how the county tagged the procurement or that fludrocortisone acetate procurement does not currently generate visible state and local competitive bidding activity at the commodity level. Practitioners pursuing this code should verify whether fludrocortisone acetate opportunities are being solicited under parent family codes for pharmaceutical supplies or scheduled purchases, or whether demand has shifted to bulk procurement frameworks and cooperative purchasing vehicles that do not post individual commodity notices.